RESMED, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 212.9 USD | -1.52% |
|
-0.99% | +23.75% |
| Sales 2024 * | 4.68B 375B | Sales 2025 * | 5.03B 404B | Capitalization | 31.27B 2,510B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.02B 82.1B | Net income 2025 * | 1.24B 99.2B | EV / Sales 2024 * | 6.82 x |
| Net Debt 2024 * | 592M 47.48B | Net cash position 2025 * | 384M 30.78B | EV / Sales 2025 * | 6.14 x |
| P/E ratio 2024 * |
30.7
x | P/E ratio 2025 * |
25.9
x | Employees | 10,140 |
| Yield 2024 * |
0.92% | Yield 2025 * |
1.01% | Free-Float | 76.95% |
More Fundamentals
* Assessed data
More news
Latest transcript on ResMed, Inc.
More recommendations
More news
| 1 day | -1.52% | ||
| 1 week | -0.99% | ||
| Current month | -0.52% | ||
| 1 month | +13.38% | ||
| 3 months | +15.85% | ||
| 6 months | +43.08% | ||
| Current year | +23.75% |
1 week
210.39
221.40
1 month
172.19221.40
Current year
164.12221.40
1 year
132.24237.26
3 years
132.24301.34
5 years
108.85301.34
10 years
45.74301.34
| Managers | Title | Age | Since |
|---|---|---|---|
Mick Farrell
CEO | Chief Executive Officer | 51 | 31/08/00 |
Peter Farrell
FOU | Founder | 81 | 31/05/89 |
Brett Sandercock
DFI | Director of Finance/CFO | 57 | 31/12/97 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mick Farrell
CEO | Chief Executive Officer | 51 | 31/08/00 |
Ron Taylor
BRD | Director/Board Member | 76 | 31/12/04 |
Peter Farrell
FOU | Founder | 81 | 31/05/89 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.09% | 0 M€ | +5.54% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/05/24 | 212.9 | -1.52% | 993,127 |
| 07/05/24 | 216.2 | -0.36% | 813,938 |
| 06/05/24 | 216.9 | -0.02% | 844,821 |
| 03/05/24 | 217 | -0.54% | 655,018 |
| 02/05/24 | 218.2 | +1.46% | 1,146,122 |
Delayed Quote Nyse, May 08, 2024 at 09:00 pm
More quotes
ResMed, Inc. specializes in designing, manufacturing and marketing respiratory disorders diagnosis, treatments and management (primarily sleep respiratory disorders). Net sales break down by family of products as follows:
- medical devices (50.4%);
- masks (37.9%);
- software as a service (11.7%).
At the end of June 2021, the group had 6 production sites located in the United States (2), Australia, China, Singapore and Malaysia.
The United States accounts for 61.4% of net sales.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
212.9
USD
Average target price
216.6
USD
Spread / Average Target
+1.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +23.75% | 31.27B | |
| +8.07% | 219B | |
| +7.87% | 185B | |
| +12.75% | 135B | |
| -1.67% | 62.21B | |
| +4.88% | 51.01B | |
| +11.59% | 51.28B | |
| +2.71% | 41.85B | |
| +4.90% | 37.02B | |
| +16.28% | 23.66B |
- Stock Market
- Equities
- RMD Stock
